Another two eligible trials12,20 compared sequential anthracycline plus taxane with concurrent taxane plus carboplatin in specific tumour subtypes: HER2-positive tumours in the BCIRG-006 trial (n=2149)12 and triple-negative tumours in the PATTERN trial (n=647).20 Again, with sequential administration, cumulative taxane doses were lower with anthracycline plus taxane than with the non-anthracycline comparator, and cumulative anthracycline doses were lower than with concurrent anthracycline plus taxane (doses for each trial are provided in figure 1). This evidence concerns the gene ERBB2 and neoplasm.